- Home
- BSTZ vs EWTX Comparison
BSTZ vs EWTX Comparison
Compare BSTZ & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSTZ
- EWTX
- Stock Information
- Founded
- BSTZ 2019
- EWTX 2017
- Country
- BSTZ United States
- EWTX United States
- Employees
- BSTZ N/A
- EWTX N/A
- Industry
- BSTZ Trusts Except Educational Religious and Charitable
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- BSTZ Finance
- EWTX Health Care
- Exchange
- BSTZ Nasdaq
- EWTX Nasdaq
- Market Cap
- BSTZ 1.5B
- EWTX 1.5B
- IPO Year
- BSTZ N/A
- EWTX 2021
- Fundamental
- Price
- BSTZ $21.83
- EWTX $14.45
- Analyst Decision
- BSTZ
- EWTX Buy
- Analyst Count
- BSTZ 0
- EWTX 9
- Target Price
- BSTZ N/A
- EWTX $39.89
- AVG Volume (30 Days)
- BSTZ 303.2K
- EWTX 675.4K
- Earning Date
- BSTZ 01-01-0001
- EWTX 08-07-2025
- Dividend Yield
- BSTZ 8.31%
- EWTX N/A
- EPS Growth
- BSTZ N/A
- EWTX N/A
- EPS
- BSTZ 0.71
- EWTX N/A
- Revenue
- BSTZ N/A
- EWTX N/A
- Revenue This Year
- BSTZ N/A
- EWTX N/A
- Revenue Next Year
- BSTZ N/A
- EWTX N/A
- P/E Ratio
- BSTZ $26.69
- EWTX N/A
- Revenue Growth
- BSTZ N/A
- EWTX N/A
- 52 Week Low
- BSTZ $14.11
- EWTX $10.60
- 52 Week High
- BSTZ $19.43
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- BSTZ 61.15
- EWTX 55.50
- Support Level
- BSTZ $20.49
- EWTX $14.18
- Resistance Level
- BSTZ $21.62
- EWTX $15.21
- Average True Range (ATR)
- BSTZ 0.31
- EWTX 0.61
- MACD
- BSTZ -0.01
- EWTX 0.11
- Stochastic Oscillator
- BSTZ 89.31
- EWTX 74.01
About BSTZ BlackRock Science and Technology Term Trust of Beneficial Interest
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.